1,4,6,7-tetrahydropyrano[4,3-b]pyrrole-2-carboxylic acid | 1263083-03-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1,4,6,7-tetrahydropyrano[4,3-b]pyrrole-2-carboxylic acid
• 英文别名: 1H,4H,6H,7H-pyrano[4,3-b]pyrrole-2-carboxylic acid
• CAS: 1263083-03-9
• 化学式: C₈H₉NO₃
• mdl: MFCD22068040
• 分子量: 167.164
• InChiKey: UBSCTSBSAAFJLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  62.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-甲基哌嗪 、 1,4,6,7-tetrahydropyrano[4,3-b]pyrrole-2-carboxylic acid 在 N-甲基吗啉 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以33%的产率得到(4-Methylpiperazin-1-yl)-(1,4,6,7-tetrahydropyrano[4,3-b]pyrrol-2-yl)methanone
  参考文献：
  名称：

  EP2460794

  摘要：

  公开号：
• 作为产物：
  描述：

  1,4,6,7-tetrahydropyrano[4,3-b]pyrrole-2-carboxylic acid ethyl ester 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 1,4,6,7-tetrahydropyrano[4,3-b]pyrrole-2-carboxylic acid
  参考文献：
  名称：

  [EN] COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  [FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS D'UTILISATION

  摘要：

  公开号：

  WO2018119395A8

文献信息

• MCL-1 INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20190352271A1

  公开（公告）日：2019-11-21

  The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

  本公开涉及通常用于治疗癌症的化合物和药物组合物。
• MCL-1 inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US10703733B2

  公开（公告）日：2020-07-07

  The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

  本公开内容一般涉及可用于治疗癌症方法的化合物和药物组合物。
• COMPOUNS, COMPOSITIONS AND METHODS OF USE
  申请人：Aquinnah Pharmaceuticals Inc.

  公开号：EP3557998A1

  公开（公告）日：2019-10-30
• PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE
  申请人：Tachibana Yuuki

  公开号：US20120277238A1

  公开（公告）日：2012-11-01

  The present invention provides a compound which indicates a histamine H4 receptor modulating activity. A compound represented by a formula (I): wherein A ring is a ring represented by the following formula: wherein R 1 is substituted or unsubstituted alkyl, etc., W is —O—, etc., n is an integer of 0 to 6; X is —N(R 7 )— or —O—; R 7 is hydrogen, substituted or unsubstituted alkyl, etc.; Y is —C(R 8 )═ or —N═; R 8 is hydrogen, substituted or unsubstituted alkyl, etc.; Z is ═O, ═S, etc.; B ring is a ring represented by the following formula: wherein R 10 is each independently substituted or unsubstituted alkyl, halogen, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted amino; R 11 , R 12a and R 12b are each independently hydrogen or substituted or unsubstituted alkyl, etc.; p is an integer of 0 to 4, or its pharmaceutically acceptable salt, or a solvate thereof.
• COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：Aquinnah Pharmaceuticals, Inc.

  公开号：US20200270211A1

  公开（公告）日：2020-08-27

  Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.